Massachusetts Society of Clinical Oncologists - FDA Approves cabozantinib (CABOMETYX) for patients with HCC

"The voice for cancer physicians and their patients in Massachusetts."

Home
For Professionals
FDA Approvals
FDA Approves cabozantinib (CABOMETYX) for patients with HCC

FDA Approves cabozantinib (CABOMETYX) for patients with HCC

15 Jan 2019 2:45 PM | Anonymous

The U.S. Food and Drug Administration approved cabozantinib (Cabometyz; Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org